Buprenorphine and Zolpidem: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Zolpidem
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Buprenorphine (like Belbuca or Sublocade) is an opioid, and zolpidem (Ambien) is a sleep medicine. Both slow down your brain and your breathing. When you take them together, those calming effects can stack up. That can lead to heavy drowsiness, very slow or shallow breathing, and in serious cases loss of consciousness. This is a real safety concern, so it matters.
The good news is your care team can manage this. Do not stop either medicine on your own. Instead, tell your doctor or pharmacist you take both. They can adjust doses, watch you more closely, or suggest a safer option for sleep. Reach out right away if you feel unusually sleepy, confused, or short of breath.
Effect: Additive CNS and respiratory depression when buprenorphine (partial opioid agonist) is combined with zolpidem (a non-benzodiazepine "Z-drug" hypnotic that potentiates GABA-A signaling). This is a pharmacodynamic, not pharmacokinetic, interaction; neither agent's metabolism drives the risk.
- Direction: Increased sedation, profound somnolence, respiratory depression, potential coma/death.
- Evidence: Probable; supported by epidemiologic overdose data.
- Severity: Major. Onset unspecified.
Management: Avoid concomitant use where possible; taper zolpidem or use lowest effective dose. If combined, monitor respiratory status and sedation, consider alternative insomnia therapy. Do not withhold MAT because of hypnotic use.
What happens
An increased risk of respiratory depression and CNS depression
Interaction Deep Dive
When buprenorphine is given together with a CNS depressant, the CNS depressant effects can combine, raising the likelihood of respiratory depression, deep sedation, coma, and death. Discontinuing CNS depressants is favored rather than using them at the same time. Depending on the situation, it may be suitable to observe the patient at a higher level of care or to implement a taper. In other situations, it may be appropriate to slowly wean a patient from a prescribed CNS depressant or to reduce it to the smallest effective dose. When simultaneous use cannot be avoided, exercise careful monitoring and management, and think about alternative approaches for managing anxiety or insomnia2. A Swedish epidemiological study found that patients on methadone- or buprenorphine-based medication-assisted treatment (MAT) who also took benzodiazepines or other CNS depressants (for instance, medications used for insomnia) had a heightened risk of death. Based on an analysis of pooled national death certificate data spanning 2010 to 2014, most overdose deaths involving buprenorphine and methadone also involved concurrent CNS depressant use. Whether the risk of overdose death from concurrent CNS depressant drugs varies between buprenorphine and methadone is not known 3.
Why it happens (mechanism)
Additive CNS depression
How to manage this interaction
Both drugs calm the nervous system, so used together they raise the risk of over-sedation and slowed breathing. Your care team has clear ways to handle this.
- Keep taking both as prescribed unless your doctor tells you otherwise. Do not stop your buprenorphine.
- Your team may lower the zolpidem to the lowest dose that works, gradually taper it, or switch you to a different sleep option.
- They may watch you more closely, especially for breathing and heavy drowsiness.
- Tell your pharmacist or prescriber that you take both, and report unusual sleepiness, confusion, or trouble breathing right away.
- Avoid alcohol and other sedatives, which add to the risk.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
2 reports — tap to read
a) A Swedish epidemiological study found that patients on methadone- or buprenorphine-based medication-assisted treatment (MAT) who also took benzodiazepines or other CNS depressants (for example, agents used to treat insomnia) have a higher risk of death. Among MAT-prescribed patients (aged 18 to 50), the periods during which CNS depressants were prescribed were compared with periods without CNS depressant therapy to evaluate the risk of fatal overdose, non-overdose related mortality, and all-cause mortality between July 1, 2005 and December 31, 2012. The findings showed an increased risk of all-cause mortality (adjusted hazard ratio (HR) 1.44; 95% CI, 0.93 to 2.23) and non-overdose related mortality (HR 1.74; 95% CI 1.00 to 3.01) with MAT combined with benzodiazepine treatment; however, these data were not deemed statistically significant. Although the results indicated an increased risk of fatal overdose, non-overdose mortality, and all-cause mortality during periods of coadministration of MAT and non-benzodiazepines, only the data for fatal overdose and all-cause mortality reached statistical significance; HR 2.34 (95% CI, 1.37 to 3.99) and HR 1.33 (95% CI, 1.12 to 2.45), respectively. The authors did not compare the benzodiazepine cohort with the non-benzodiazepine cohort because they did not adjust for the indication for use of the drugs 3.
b) A study of pooled nationwide death certificate data from 2010 to 2014 documented 3495 drug overdose deaths in 2014. Methadone and other CNS depressants were commonly cited as contributors to those deaths. Concurrent ALPRAZolam use appeared in 18.1% of cases, followed by oxyCODONE (10.1%), cocaine (9.6%), heroin (9%), and diazePAM (6.6%). The FDA documented 322 drug overdose deaths in 2014 that involved buprenorphine. Of these 322 deaths, 32.9% involved ALPRAZolam, 17.4% involved clonazePAM, 11.2% involved diazePAM, 11.2% involved heroin, and 9.9% involved fentaNYL. The absolute number of methadone-involved deaths was 10 times the number of buprenorphine-involved deaths, though confounding factors and differences in drug utilization were not taken into account. Whether the risk of overdose death with concurrent CNS depressant drugs differed between buprenorphine and methadone is unknown 3.
Common questions
Can I take Buprenorphine and Zolpidem together?
Buprenorphine and zolpidem both depress the brain and breathing, so combining them is a major safety concern. Keep taking both as prescribed, but tell your doctor or pharmacist so they can adjust the dose, monitor you, or find a safer sleep option. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Zolpidem interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Zolpidem interaction managed?
Both drugs calm the nervous system, so used together they raise the risk of over-sedation and slowed breathing. Your care team has clear ways to handle this. Keep taking both as prescribed unless your doctor tells you otherwise. Do not stop your buprenorphine. Your team may lower the zolpidem to the lowest dose that works, gradually taper it, or switch you to a different sleep option. They may wat… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Zolpidem need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: SUBUTEX(R) sublingual tablets, buprenorphine sublingual tablets. Indivior Inc (per FDA), North Chesterfield, VA, 2021. DailyMed
- US Food and Drug Administration (FDA): Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food and Drug Administration (FDA). Silver Spring, MD. 2017.
Keep reading about Buprenorphine
Keep reading about Zolpidem
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist